Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review-Reference-Cited by-同舟云学术

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review

Published:2019-03-04 Issue:3 Volume:38 Page:601-611
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Kunath F.,Goebell P. J.,Wullich B.,Sikic D.,Kahlmeyer A.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-019-02704-y.pdf

Reference54 articles.

1. Antonarakis ES, Eisenberger MA (2009) Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nat Clin Pract Oncol 6(1):12–13

2. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790

3. Shore ND (2017) Darolutamide (ODM-201) for the treatment of prostate cancer. Expert Opin Pharmacother 18(9):945–952

4. Al-Salama ZT (2018) Apalutamide: first global approval. Drugs 78(6):699–705

5. Hammerer PG, Wirth MP, Group EED-NL-s (2018) Health-related quality of life in 536 long-term prostate cancer survivors after treatment with leuprorelin acetate: a combined retrospective and prospective analysis. Urol Int 100(1):72–78

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-in-One Polymeric NO-Donor Prodrugs Mediate Precision and Synergistic Prostate Cancer Treatment;ACS Applied Materials & Interfaces;2023-07-06

2. UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer;Canadian Urological Association Journal;2022-09-26

3. Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker;Urologic Oncology: Seminars and Original Investigations;2022-08

4. Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data;Current Opinion in Urology;2020-07

5. Navigating systemic therapy for metastatic castration-naïve prostate cancer;World Journal of Urology;2020-01-02